Submit to Special Issue Submit Abstract to Special Issue Review for Vaccines Edit a Special Issue

Journal Browser

► Journal Browser

Special Issue "Vaccines for Infectious and Chronic Diseases 2.0"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 30 September 2023 | Viewed by 7708

Share This Special Issue

Special Issue Editors

Prof. Dr. Vasso Apostolopoulos

E-Mail Website
Guest Editor

Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
Interests: immunology; drugs; vaccines; autoimmune disorders; cancer; infectious diseases; prevention of chronic diseases; healthy ageing; mental health; drug addiction; SARS-CoV-2
Special Issues, Collections and Topics in MDPI journals

Dr. Jack Feehan

E-Mail Website
Guest Editor

Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
Interests: immunology; inflammation; vaccines; chronic disease; autoimmune diseases; brain diseases; healthy ageing
Special Issues, Collections and Topics in MDPI journals

Dr. Vivek P. Chavda

E-Mail Website
Guest Editor

Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380008, Gujarat, India
Interests: immunology; inflammation; vaccine formulations; vaccine validations; biologics; immunotherapeutics; antigen delivery; infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on naturaceuticals (natural products) and vaccine development for bacterial and viral infections, cancer, autoimmunity and chronic diseases. This is Series-II following the success of series-I. Submission of original articles, systematic reviews, short communications, and other types of article on related topics are welcome. Manuscripts will follow standard Journal peer-review practices, and those accepted for publication will appear in the Special Issue on Vaccines for Infectious and Chronic Diseases. We look forward to receiving and welcome your contributions.

Prof. Dr. Vasso Apostolopoulos
Dr. Jack Feehan
Dr. Vivek P. Chavda
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

vaccine
formulations
adjuvant
antigen
vaccine immunity
delivery systems
vaccine stability
animal models for vaccine efficacy
human clinical trials
vitamins
naturaceuticals
diseases covered:
- cancer
- infectious diseases
- pathogens (bacterial, viral)
- chronic diseases
- autoimmunity

Published Papers (5 papers)

Download All Papers

Editorial

Jump to: Research, Review

Open AccessEditorial

The Emergence of Hybrid Variants of SARS-CoV-2: Towards Hybrid Immunity

and

Vaccines 2023, 11(4), 764; https://doi.org/10.3390/vaccines11040764 - 30 Mar 2023

Viewed by 651

Abstract

In this review work, the authors emphasize the discussion on different emerging variants of SARS-CoV-2 and vaccine effectiveness against them [...] Full article

(This article belongs to the Special Issue Vaccines for Infectious and Chronic Diseases 2.0)

► Show Figures

Figure 1

Research

Jump to: Editorial, Review

Open AccessArticle

Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization

and

Vaccines 2023, 11(2), 340; https://doi.org/10.3390/vaccines11020340 - 02 Feb 2023

Viewed by 1171

Abstract

Background: Methamphetamine (METH) substance-use disorder is an ever-growing global health issue with no effective treatment. Anti-METH vaccines are under investigation as an alternative to existing psychological interventions. This platform has made significant progress over past decades mainly in preclinical stages, and efforts to develop an anti-METH vaccine with a high antibody response are of utmost importance. Methodology: A novel conjugated anti-METH vaccine was developed using METH HCl as the starting material for the design of hapten, a peptide linker consisting of five lysines and five glycines, and finally immunogenic carrier mannan, which is novel to this platform. All the chemical reaction steps were confirmed by several analytical techniques, and the immunogenicity of the developed vaccine was investigated in a mouse model. Results: Thin-layer chromatography and gas chromatography confirmed the reaction between METH and peptide linker. UV, NMR and color tests were used to confirm the presence of the aldehyde groups in oxidized mannan (OM). The final conjugated vaccine was confirmed by UV and LC-MS. The stability of mannan, the METH hapten, and the final vaccine was evaluated by UV and LC-MS and demonstrated satisfactory stability over 3 months in various storage conditions. Animal studies supported the immunogenicity of the novel vaccine. Conclusions: We successfully developed and characterized a novel METH vaccine in vitro and in vivo. The present study findings are encouraging and will form the basis of further exploration to assess its effectiveness to prevent METH addiction in preclinical models. Full article

(This article belongs to the Special Issue Vaccines for Infectious and Chronic Diseases 2.0)

► Show Figures

Figure 1

Open AccessCommunication

Inhalable Vaccines: Can They Help Control Pandemics?

Vivek P. Chavda

Lalitkumar K. Vora

and

Vasso Apostolopoulos

Vaccines 2022, 10(8), 1309; https://doi.org/10.3390/vaccines10081309 - 13 Aug 2022

Cited by 7 | Viewed by 1246

Abstract

The emergence of a new coronavirus presents a huge risk to public health worldwide and has spread widely amongst the human population. Since its emergence, the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is frequently evolving by mutation and genetic recombination to give rise to new viral variants. These emerging variants pose a challenge to existing COVID-19 management strategies and vaccine efficacy. Interruption of viral spread is required as the merging variants pose higher transmissibility than the previous ones. To achieve this, local protection of the respiratory tract with immunity is essential. Here, we advocate the use of pulmonary/inhalable vaccines to achieve this goal. Full article

(This article belongs to the Special Issue Vaccines for Infectious and Chronic Diseases 2.0)

► Show Figures

Figure 1

Review

Jump to: Editorial, Research

Open AccessReview

mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics

and

Vaccines 2022, 10(12), 2150; https://doi.org/10.3390/vaccines10122150 - 15 Dec 2022

Cited by 9 | Viewed by 1927

Abstract

An unheard mobilization of resources to find SARS-CoV-2 vaccines and therapies has been sparked by the COVID-19 pandemic. Two years ago, COVID-19’s launch propelled mRNA-based technologies into the public eye. Knowledge gained from mRNA technology used to combat COVID-19 is assisting in the creation of treatments and vaccines to treat existing illnesses and may avert pandemics in the future. Exploiting the capacity of mRNA to create therapeutic proteins to impede or treat a variety of illnesses, including cancer, is the main goal of the quickly developing, highly multidisciplinary field of biomedicine. In this review, we explore the potential of mRNA as a vaccine and therapeutic using current research findings. Full article

(This article belongs to the Special Issue Vaccines for Infectious and Chronic Diseases 2.0)

► Show Figures

Figure 1

Open AccessReview

Immunotherapies for Alzheimer’s Disease—A Review

and

Vaccines 2022, 10(9), 1527; https://doi.org/10.3390/vaccines10091527 - 14 Sep 2022

Cited by 5 | Viewed by 2247

Abstract

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of dementia and is characterised by the presence of highly neurotoxic amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) of tau protein within the brain. Historically, treatments for AD have consisted of medications that can slow the progression of symptoms but not halt or reverse them. The shortcomings of conventional drugs have led to a growing need for novel, effective approaches to the treatment of AD. In recent years, immunotherapies have been at the forefront of these efforts. Briefly, immunotherapies utilise the immune system of the patient to treat a condition, with common immunotherapies for AD consisting of the use of monoclonal antibodies or vaccines. Most of these treatments target the production and deposition of Aβ due to its neurotoxicity, but treatments specifically targeting tau protein are being researched as well. These treatments have had great variance in their efficacy and safety, leading to a constant need for the research and development of new safe and effective treatments. Full article

(This article belongs to the Special Issue Vaccines for Infectious and Chronic Diseases 2.0)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Special Issue "Vaccines for Infectious and Chronic Diseases 2.0"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (5 papers)

Editorial

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI